Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Withdrawn

Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease

Condition

Gastrointestinal tract

6 February 2026

Published on 01 Jul 2022
Last Updated on 06 Feb 2026


Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease Guidance is outdated and has been withdrawn on 1 February 2026.

Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease (Withdrawn 6 Feb 2026) [PDF, 131 KB]

PES Treatments for ulcerative colitis and Crohn’s disease (Withdrawn 6 Feb 2026) [PDF, 188 KB]

Back to top